Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well abiraterone acetate, niclosamide,
and prednisone work in treating patients with hormone-resistant prostate cancer. Androgens
can cause the growth of prostate cells. Hormone therapy using abiraterone acetate may fight
prostate cancer by lowering the amount of androgen the body makes. Niclosamide is a drug that
may block another signal that can cause prostate cancer cell growth. Prednisone is a drug
that can help lessen inflammation. Giving abiraterone acetate, niclosamide, and prednisone
may be a better treatment for patients with hormone-resistant prostate cancer.